drugset / Trial / NCT00575068
Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never been studied in patients with lymphoma, however, it has been studied in psoriasis patients at various dose levels and schedules.
Timeline
- Start
- 2002-01
- Primary completion
- 2002-09
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | galiximab | Monoclonal antibody | 125 mg/m2 | — |
| Subject | galiximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | galiximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | galiximab | Monoclonal antibody | 500 mg/m2 | — |